OBJECTIVE: The association between human epidermal growth factor receptor 3 (HER3) overexpression and survival in patients with curatively resected pancreatic cancer was investigated. METHODS: Tissue samples from 126 pancreatic cancers without hematogenous or peritoneal metastases recovered from macroscopically curative resection were fixed with formalin, embedded in paraffin and subjected to immunohistochemical staining. Semiquantitative scores of zero (no staining or staining in less than 10% of cancer cells), 1+, 2+, or 3+ were assigned to each sample based on the intensity of staining. Scores of 2+ or 3+ were defined as HER3-positive staining, i.e., HER3 overexpression. RESULTS: HER3 overexpression was observed in 52 of the 126 tissue samples (41.3%). There were no associations between HER3 overexpression and clinicopathological factors, including tumor location, tumor size, tumor differentiation, T/N categories according to the International Union against Cancer, and serum carbohydrate antibody 19-9 level (CA19-9). Univariate analysis demonstrated the median survival time of patients with HER3 overexpression was 37.2 months, while that of patients with HER3-negative samples was 58.6 months (p = 0.008). HER3 overexpression, lymph node metastasis, and elevated serum CA19-9 level were independent predictors of poor prognosis based on multivariate survival analysis. CONCLUSION: A new prognostic predictor, HER3 overexpression, was identified for resected pancreatic cancer.
OBJECTIVE: The association between human epidermal growth factor receptor 3 (HER3) overexpression and survival in patients with curatively resected pancreatic cancer was investigated. METHODS: Tissue samples from 126 pancreatic cancers without hematogenous or peritoneal metastases recovered from macroscopically curative resection were fixed with formalin, embedded in paraffin and subjected to immunohistochemical staining. Semiquantitative scores of zero (no staining or staining in less than 10% of cancer cells), 1+, 2+, or 3+ were assigned to each sample based on the intensity of staining. Scores of 2+ or 3+ were defined as HER3-positive staining, i.e., HER3 overexpression. RESULTS:HER3 overexpression was observed in 52 of the 126 tissue samples (41.3%). There were no associations between HER3 overexpression and clinicopathological factors, including tumor location, tumor size, tumor differentiation, T/N categories according to the International Union against Cancer, and serum carbohydrate antibody 19-9 level (CA19-9). Univariate analysis demonstrated the median survival time of patients with HER3 overexpression was 37.2 months, while that of patients with HER3-negative samples was 58.6 months (p = 0.008). HER3 overexpression, lymph node metastasis, and elevated serum CA19-9 level were independent predictors of poor prognosis based on multivariate survival analysis. CONCLUSION: A new prognostic predictor, HER3 overexpression, was identified for resected pancreatic cancer.
Authors: Frederike Bensch; Laetitia E Lamberts; Michaël M Smeenk; Annelies Jorritsma-Smit; Marjolijn N Lub-de Hooge; Anton G T Terwisscha van Scheltinga; Johan R de Jong; Jourik A Gietema; Carolien P Schröder; Marlene Thomas; Wolfgang Jacob; Keelara Abiraj; Celine Adessi; Georgina Meneses-Lorente; Ian James; Martin Weisser; Adrienne H Brouwers; Elisabeth G E de Vries Journal: Clin Cancer Res Date: 2017-07-21 Impact factor: 12.531
Authors: Jacob Elebro; Margareta Heby; Carl Fredrik Warfvinge; Björn Nodin; Jakob Eberhard; Karin Jirström Journal: PLoS One Date: 2016-04-12 Impact factor: 3.240
Authors: Brooke N McKnight; Akhila N W Kuda-Wedagedara; Kuntal K Sevak; Dalya Abdel-Atti; Wendy N Wiesend; Anson Ku; Dakshnamurthy Selvakumar; Sean D Carlin; Jason S Lewis; Nerissa T Viola-Villegas Journal: Sci Rep Date: 2018-06-13 Impact factor: 4.379